Post has attachment

Keen to be involved in an OS TB project, but work on the testing side rather than the chemistry. If you want stuff testing, happy to chat! 

Post has attachment
Celerion is conducting a study for men & women with Tuberculosis ages 19-50.

To learn more visit http://ow.ly/LgK1V
Photo

Post has attachment
New open source drug candidate series to explore, originating from GSK. We're looking at it, and anyone else is free to jump in. Promising initial data. Now seeking analogs. #tuberculosis  

Post has attachment

Post has attachment

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Evidence another compound, BM212, also targets MmpL3. 10.1128/AAC.05270-11.  "The 1,5-diarylpyrrole derivative BM212 was previously shown to be active against multidrug-resistant clinical isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria. To determine its mechanism of action, we identified the cellular target. Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated. By the screening of genomic libraries and by whole-genome sequencing, we found that all the characterized mutants showed mutations in the mmpL3 gene, allowing us to conclude that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family. Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil. Uptake/efflux experiments with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212. Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212."
Wait while more posts are being loaded